Clinical Trial Update: Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study [NA]

View source ↗

Summary

ClinicalTrials.gov update on the CARE study evaluating enhanced risk assessments for women with BRCA1/2 mutations; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Breast and Ovarian Cancer Syndrome

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome | NA | Status: COMPLETED